ZAP Surgical Announces Upcoming Installation of Next-Generation ZAP-X Gyroscopic Radiosurgery in Ankara, Turkey

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year. Patient treatments are expected to begin in early 2024.

Hacettepe University Hospital is among the highly esteemed Turkish institutions on the international platform and holds a leading position in medical education. Hacettepe has become the preeminent healthcare center of Turkey and proudly serves as a major training center for Hacettepe University Faculty of Medicine students and residents.

“When treating the brain with radiosurgery, every intricate detail matters to achieve the optimal outcome,” said Dr. Gokhan Ozyigit, Professor of Radiation Oncology at Hacettepe University. “Dedicated to treat only cranial indications without using Cobalt-60 radioactive sources, the ZAP-X will allow for world-class treatments that aren’t feasible with many multi-purpose radiotherapy systems designed to treat breast, lung, and prostate cancers. We have more than two decades of experience with stereotactic radiosurgery. Thus, we will not restrict ourselves only to treat brain lesions with ZAP-X, but also treat orbital and recurrent upper head and neck region tumors such as uveal melanomas and recurrent nasopharyngeal cancers. We are excited to further expand the world-class capabilities of our department with ZAP-X.”

Stereotactic radiosurgery (SRS) offers a non-invasive and painless procedure for many primary and metastatic brain tumors, as well as other cranial disorders such as trigeminal neuralgia and arteriovenous malformations (AVM). For select indications, radiosurgery has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.

With its ground-breaking design, the ZAP-X system uses unique gyroscopic mobility to direct radiosurgical beams from hundreds of unique angles to precisely concentrate radiation on the tumor target. This pioneering approach supports the clinical objective of protecting healthy brain tissue and preserving patient cognitive function. The vault-free, cobalt-free ZAP-X is also renowned for eliminating the expense of building costly shielded radiation treatment rooms, and removing the need to maintain, secure and regularly replace live radioactive isotopes for radiation beam production.

“Hacettepe University Hospital has always been at the forefront of the most advanced medical technology,” says Hakan Baraner, ZAP Surgical’s Senior Vice President for Europe, India, Middle East, and Africa (EIMEA). “With the addition of ZAP-X, they will further reinforce their reputation as global center of medical excellence.”


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy